Tablets, Lozenges, Or Pills Patents (Class 424/464)
  • Patent number: 10660957
    Abstract: The present invention provides compositions and methods for treating and preventing an A?-modulated disease. In certain embodiments, the invention provides an inhibitor of Fyn tyrosine kinase, and methods of using the same. In certain embodiments, the inhibitor of the invention inhibits A? oligomer induced signaling and reduces or halts the progression of Alzheimer's Disease.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: May 26, 2020
    Assignee: Yale University
    Inventor: Stephen M. Strittmatter
  • Patent number: 10653629
    Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 19, 2020
    Assignee: Amorsa Therapeutics, Inc.
    Inventors: Alex Nivorozhkin, Nelson Landrau
  • Patent number: 10632074
    Abstract: The present invention provides a composite granulated product that is optimal for allowing a tablet, preferably an orally disintegrating tablet (OD tablet) to be excellent in disintegrability and have proper hardness. The composite granulated product includes a sugar or a sugar alcohol, a swelling binder, a disintegrating agent, and a highly absorbent excipient.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 28, 2020
    Assignee: DAIDO CHEMICAL CORPORATION
    Inventors: Shunji Uramatsu, Toshinobu Uemura, Masakazu Morizane, Toshio Shimamoto
  • Patent number: 10617660
    Abstract: Compositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 14, 2020
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 10603284
    Abstract: The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 31, 2020
    Assignee: Applied Materials, Inc.
    Inventors: Pekka Hoppu, Tommi Kaariainen, Marja-Leena Kaariainen, Aimo Turunen
  • Patent number: 10568856
    Abstract: Compositions are disclosed for improved sleep quality and quantity including ingredients for both immediate release and controlled release. The invention provides improved supplemental compositions, and methods for administering same to a user, for enhancing the onset, quality, and duration of sleep in humans and animals. The supplemental composition may contain a combination of ingredients in proportions calculated to relieve stress, promote relaxation, and enhance sleep, including at least the following ingredients: L-Theanine, Skullcap Herb (Scutellaria lateriflora L.), Rhodiola (Rhodiola rosea L.), and Chamomile Flower (Matricaria Recutita). In addition, the supplemental composition may include the secondary ingredient Melatonin. The selection and amounts of the ingredients of the supplemental composition promote sleep onset, quality, and duration and may be provided for consumption at least one time daily, e.g., prior to sleep.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: February 25, 2020
    Inventors: John Doherty, Soring Popa, Dore Miller, Marc Bellemore
  • Patent number: 10526358
    Abstract: The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: January 7, 2020
    Assignee: THAR PHARMA, LLC
    Inventors: Mazen Hanna, Ning Shan, David R. Weyna, Miranda L. Cheney
  • Patent number: 10517846
    Abstract: The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 31, 2019
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Yogesh Bapurao Pawar, Kailas Khomane, Saurabh Srivastava, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Patent number: 10517834
    Abstract: The present disclosure is directed to compositions and methods for the production of a fast dissolving tablets to be used for the delivery of an agent. An agent can be an active pharmaceutical agent or a non-pharmacological agent, which is needed to be delivered by means of a fast dissolving delivery system. The invention solves many industry challenges within the field of fast dissolve technologies, specifically coupling of fast dissolve properties with required physical attributes of strength/robustness required for commercial production and distribution.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 31, 2019
    Inventor: Owen Murray
  • Patent number: 10507203
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 17, 2019
    Assignee: TRIS PHARMA, INC
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 10493096
    Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: December 3, 2019
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10478396
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: November 19, 2019
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10478420
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 19, 2019
    Assignee: ObsEva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • Patent number: 10471071
    Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 12, 2019
    Assignee: Adare Pharmaceuticals, Inc.
    Inventors: Michael A. Gosselin, Jin-Wang Lai, Gopi M. Venkatesh
  • Patent number: 10456393
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 29, 2019
    Assignee: Persion Pharmaceuticals LLC
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • Patent number: 10440983
    Abstract: The invention relates to a microcapsule comprising at least one active substance selected from lutein and lutein esters embedded in a matrix comprising fish gelatine and optionally one or more other matrix components, wherein the content of said at least one active substance calculated as free lutein is from 0.5 to 25% of total weight of the microcapsule, and which microcapsule does not comprise any added emulsifier. The invention further relates to a process of preparing the microcapsule as well as uses and products comprising the microcapsule.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: October 15, 2019
    Assignee: BASF SE
    Inventors: Nina Musaeus, Inge-Lise Krylbo
  • Patent number: 10426838
    Abstract: A composite particle comprising from 50 to 80 parts by mass of cellulose, from 10 to 40 parts by mass of an inorganic compound and from 4 to 11 parts by mass of hydroxypropyl cellulose based on 100 parts by mass of a total of contents of the cellulose, the inorganic compound and the hydroxypropyl cellulose.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 1, 2019
    Assignee: ASAHI KASEI KABUSHIKI KAISHA
    Inventors: Yosuke Honda, Kazuhiro Obae, Hanayo Kodama
  • Patent number: 10426732
    Abstract: An object of the present invention is to provide an orally disintegrating tablet (ultrafast-disintegrating tablet) having an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said ultrafast-disintegrating tablet without such a complicated process as freeze-drying. This invention relates to an orally disintegrating tablet having a specific surface area of from 1.50 to 2.50 mm2/mg and a weight of from 10 to 50 mg, particularly having a disintegration time in water of 7 seconds or less and an oral disintegration time of 5 seconds or less, a method for the production of said orally disintegrating tablet, and to a disintegrative particulate composition for use in said method.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 1, 2019
    Assignee: DAICEL CORPORATION
    Inventors: Naohiro Hashikawa, Tomohito Okabayashi, Yoshihisa Takigawa, Atsuhiro Uetomo
  • Patent number: 10413514
    Abstract: Disclosed is a controlled-release solid preparation, which consists of an internal core and a coating layer, wherein part of the surface of the internal core is not covered with the coating, and is exposed to the surface of the solid preparation. Since the medicament just releases at the exposed part, the aim of controlled release can be achieved by controlling this exposed surface area.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 17, 2019
    Assignee: OVERSEAS PHARMACEUTICALS, LTD.
    Inventor: Xiaoguang Wen
  • Patent number: 10391094
    Abstract: Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: August 27, 2019
    Assignee: Impact Biomedicines, Inc.
    Inventors: Arvind Jayan, Janice Cacace
  • Patent number: 10376470
    Abstract: Solid dosage formulations containing a combination of rosuvastatin and ezetimibe, as well as methods of making such solid dosage forms and method of treating patients with fixed combination solid dosage forms of rosuvastatin and ezetimibe are provided here.
    Type: Grant
    Filed: August 27, 2017
    Date of Patent: August 13, 2019
    Assignee: Althera Life Sciences, LLC
    Inventors: Marie Charmaine Dias, Chandir Ramani
  • Patent number: 10376521
    Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 13, 2019
    Assignee: University of South Florida
    Inventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
  • Patent number: 10376483
    Abstract: A method of delivering a daily dose of hydroxycitric acid in the form of a salt as a single bolus that is as effective or more so than the same amount of active delivered via two or three administrations (b.i.d. or t.i.d.) using current delivery modalities. The method reduces the rate of occurrence of common adverse events with hydroxycitric acid salts, and reduces the occurrence of reverse effects on diets high in fat and/or alcohol. The method improves the uptake of the active compound thereby reducing the dose required.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: August 13, 2019
    Assignee: Glykon Technologies Group, LLC
    Inventors: Dallas L. Clouatre, Daniel E. Clouatre, Brad J. Douglass
  • Patent number: 10369100
    Abstract: Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 6, 2019
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Roland Greinwald, Ralph Mueller, Markus Proels, Rudolf Wilhelm
  • Patent number: 10370335
    Abstract: The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I wherein R1, R2, R3, R5, R6 and R7 are independently X3R where R is selected from the group consisting of H, halo; optionally substituted saccharide, aliphatic, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; —P(O)(ORa)(ORb) and —NRaRb, where Ra and Rb are independently H, optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; X1, X2 and X3 are independently —C(O)O—, —OC(O)—, —C(O)NH—, —NHC(O)—, —OC(O)NH—, —NHC(O)O—, —OS(O)y—, —S(O)y—, —O—, —NHC(O)—, —NHC(O)O—, —S(O)2NH—, a bond or absent; where y is an integer from 0 to 3; and R4 and R8 are independently H, (?O); hydroxy; or optionally substituted saccharide, aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or —P(O)(ORa)(ORb) or —NRaRb, where Ra and Rb are independently H, or optionally substituted aliphatic, cycloalkyl or heterocycloalkyl, aryl or heteroaryl; or a prodrug
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: August 6, 2019
    Assignee: Naturon, Inc.
    Inventors: Neal S. Bricker, Stewart Shankel, Christopher D. Cain, Mark A. Mitchnick, Michael Schmertzler
  • Patent number: 10357461
    Abstract: A hard shell capsule includes a body and a cap cooperatively defining a hollow core hard shell capsule. Each of the body and the cap has a composition that includes a polymer forming a hard polymer structure of the body and of the cap, at least one of the body and the cap composition including a therapeutically effective amount of a drug(s) loaded throughout the body and/or cap.
    Type: Grant
    Filed: December 30, 2017
    Date of Patent: July 23, 2019
    Inventor: Hemant Narahar Joshi
  • Patent number: 10357465
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 23, 2019
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Seth Lederman, Marino Nebuloni
  • Patent number: 10350214
    Abstract: An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: July 16, 2019
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Takashi Tomimatsu, Kensuke Okazaki, Yumi Ogawa, Takahiro Yamamura
  • Patent number: 10322120
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: June 18, 2019
    Assignee: Persion Pharmaceuticals LLC
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
  • Patent number: 10322094
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 18, 2019
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10314859
    Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: June 11, 2019
    Assignee: Cytosorbents Corporation
    Inventors: Humayra Begum Ali, Thomas D. Golobish, Vincent J. Capponi, Phillip P. Chan, Wei Tai Young, Andrew Robert Scheirer
  • Patent number: 10307400
    Abstract: The present invention relates to an orally disintegrating tablet (ODT) containing asenapine maleate and to a process for preparing the ODT. In a first aspect, the present invention relates to an ODT containing asenapine maleate and low substituted hydroxypropylcellulose. In a second aspect, the present invention relates to an ODT containing crystalline asenapine maleate and the ODT is prepared using conventional tabletting techniques as direct compression and granulation. In a third aspect, the present invention relates to an ODT containing asenapine maleate and a carboxylic acid, and to the use of a carboxylic acid for enhancing storage stability of an asenapine maleate containing ODT.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: June 4, 2019
    Assignee: ALFRED E. TIEFENBACHER (GMBH & CO. KG)
    Inventors: Chaitanya Yogananda Gujjar, Bala Ramesha Chary Rallabandi, Pradip Shivraj Patwari, Ansgar Fitzner
  • Patent number: 10307376
    Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: June 4, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Anthony A. McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
  • Patent number: 10308726
    Abstract: The invention provides a crosslinked polymer, a hydrogel, a water-based fracturing fluid comprising the same, and methods of making and using thereof. The crosslinked polymer of the invention is represented by formula (I), wherein * denotes a combining site with a polymer starting material and *? denotes an optional combining site with the polymer starting material, wherein the combining sites denoted by * and *? may be located in the same polymer molecule, or in different polymer molecules, but there are at least two combining sites located in different polymer molecules; X1 and X2, which may be the same or different, are independently an oxy (—O—) or imino (—NH—) group; X3 is an oxy (—O—) or imino (—NH—) group when *? denotes a combining site with the polymer starting material, or X3 is a halogen, NH2 or OH when *? isn't a combining site with the polymer starting material.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: June 4, 2019
    Inventor: Yuan Yi
  • Patent number: 10299997
    Abstract: The invention relates to a particularly storage-stable and thixotropically stable dental prophylaxis paste for professional tooth cleaning which is very easy to use and thoroughly cleans and polishes the teeth of the patient and causes little abrasion of natural tooth substance. Such a dental prophylaxis paste may comprise: a.) a base component comprising water and humectant, b.) a cleaning body comprising a compound based on calcium phosphate in combination with pumice, c.) a buffer component, d.) a component for controlling the rheology, e.) an additive component selected from the group consisting of stabilizers, dyes, pigments and fluoridation agents, and, as wetting agent, f.) has exclusively one or more amphoteric surfactant(s), where the buffer component c.) is based on hydrogen phosphate and keeps the pH of the prophylaxis paste, measured in a 10% suspension (w/w) of the paste in water against a pH electrode, between 7 and 8.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 28, 2019
    Assignee: VOCO GmbH
    Inventors: Gerrit Lübbe, Manfred Thomas Plaumann
  • Patent number: 10293074
    Abstract: A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: May 21, 2019
    Assignee: KCI USA, Inc.
    Inventor: Lorraine Nisbet
  • Patent number: 10286023
    Abstract: The invention relates to a non-acidic Boswellia low polar gum resin extract fraction (BLPRE) in combination with biological agents for enhancing the bioavailability of the biological agents. The invention also provides composition(s) comprising a Boswellia low polar gum resin extract (BLPRE) in combination with a biological agent for increasing the bioavailability of biological agent.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: May 14, 2019
    Assignee: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti, Kiran Bhupathiraju, Venkata Krishna Raju Alluri
  • Patent number: 10285953
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: May 14, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Patent number: 10265384
    Abstract: The present invention relates to solid pharmaceutical compositions for oral administration comprising a GLP-1 agonist, an absorption enhancer which is a salt of medium-chain fatty acid, and an enteric coating as well as uses thereof.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 23, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Birgitte Nissen, Flemming S. Nielsen, Patrick W. Garibay
  • Patent number: 10258574
    Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: April 16, 2019
    Assignees: CHANGZHOU PHARMACEUTICAL FACTORY CO., LTD., CRYSTEC LTD.
    Inventors: Xuezhi Yin, Linda Sharon Daintree, Sheng Ding, Daniel Mark Ledger, Bing Wang, Wenwen Zhao, Wei Wu, Jiansheng Han
  • Patent number: 10259890
    Abstract: The invention provides a crosslinked polymer, a hydrogel, a water-based fracturing fluid comprising the same, and methods of making and using thereof. The crosslinked polymer of the invention is represented by formula (I), wherein * denotes a combining site with a polymer starting material and *? denotes an optional combining site with the polymer starting material, wherein the combining sites denoted by * and *? may be located in the same polymer molecule, or in different polymer molecules, but there are at least two combining sites located in different polymer molecules; X1 and X2, which may be the same or different, are independently an oxy (—O—) or imino (—NH—) group; X3 is an oxy (—O—) or imino (—NH—) group when *? denotes a combining site with the polymer starting material, or X3 is a halogen, NH2 or OH when *? isn't a combining site with the polymer starting material.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: April 16, 2019
    Inventor: Yuan Yi
  • Patent number: 10258631
    Abstract: The present disclosure relates to novel pharmaceutical composition for the administration of testosterone or testosterone derivatives. The present disclosure also provides methods of treatment of diseases and disorders associated with fear and anxiety, a decrease in libido, or hypogonadism.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: April 16, 2019
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDCARA PHARMACEUTICALS, LLC
    Inventors: Robert A. Josephs, Craig Herman
  • Patent number: 10251849
    Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: April 9, 2019
    Assignee: Nova Southeastern University
    Inventors: Mutasem Rawas-Qalaji, Ousama Rachid, Keith Simons, Estelle Simons
  • Patent number: 10251890
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 me
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: April 9, 2019
    Assignee: University of Kentucky
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Patent number: 10227557
    Abstract: A method for producing astaxanthin incorporates a method for producing astaxanthin-rich algae cells and a method for extracting astaxanthin therefrom. An initial feedstock comprises healthy algae, water, and nutrients. During a growth phase, carbon dioxide and light from a light source are supplied to the feedstock, thereby amplifying the algae. At least a portion of the nutrients remaining after amplification of the algae are separated from the amplified algae. During a stress phase, carbon dioxide and light are supplied to the amplified algae, thereby promoting production of astaxanthin by the amplified algae. The amplified algae and a cover are placed within an interior of an attrition mill having interior surfaces and media which are substantially non-reactive to astaxanthin and milled to release the astaxanthin from the algae. The cover limits oxidation of the released astaxanthin.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: March 12, 2019
    Assignee: Sustainable Nutrition, Inc.
    Inventors: John Carberry, Matthew John Carberry, Dennis Steven Tagrin
  • Patent number: 10221326
    Abstract: The present invention relates to an improved process for producing red iron oxide pigments by the Penniman process with nitrate (also called nitrate process or direct red process) and to apparatus for implementing this process, and also to the use of the plant for producing red iron oxide pigments by the Penniman process with nitrate.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: March 5, 2019
    Assignee: LANXESS Deutschland GmbH
    Inventors: Waldemar Czaplik, Juergen Kischkewitz, Wolfgang Oehlert, Huajun Li
  • Patent number: 10201511
    Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
    Type: Grant
    Filed: January 5, 2013
    Date of Patent: February 12, 2019
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Patent number: 10201549
    Abstract: Compositions and methods for testosterone booster injection solutions (TBIS) that includes testosterone cypionate in synergistic combination with anastrozole are disclosed. Disclosed TBIS may be administered for treating testosterone deficiency. Disclosed TBIS is an intramuscular injection. The therapeutic dosage and protocol varies, according to the individual person. Different formulations may be designed to provide higher or lower testosterone doses.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: February 12, 2019
    Assignee: Professional Compounding Centers of America (PCCA)
    Inventors: Tsu-I Catherine Wang, Bruce Vincent Biundo
  • Patent number: 10195154
    Abstract: A method for easily producing orodispersible tablets that secure an eluting behavior of a principal agent in the digestive tract and mask unpleasant taste in the oral cavity is provided. Provided is a method for producing orodispersible tablets which includes mixing an additive to a principal agent to form principal agent particles as a granulation process, coating the principal agent particles with a coating agent to form coated particles as a coating process, and tableting the coated particles to form tablets as a tableting process, wherein the additive used in the granulation process contains a pH regulator, and the coating agent used in the coating process contains a pH-dependent polymer dissolving at pH 5 or more.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 5, 2019
    Assignee: Nipro Corporation
    Inventors: Yohei Hoashi, Naohisa Katayama, Shunsuke Daidouji
  • Patent number: 10188619
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: January 29, 2019
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley